

17 January 2018

PainChek Limited (**ASX: PCK**)  
ABN 21 146 035 127  
Suite 401, 35 Lime Street, Sydney, NSW, 2000  
Registered Office: Suite 5, 95 Hay Street Subiaco WA 6008  
Phone +61 8 9388 8290  
ihobson@epattechnologies.com

**ePAT Technologies Ltd confirms company name change to PainChek Ltd.**

The company received shareholder approval today to change its name from ePAT Technologies Ltd to PainChek Ltd.

The reasons for the change were explained in the ASX announcement dated 15 December 2017 and include global brand recognition, established international PainChek trademarks and domain names and ensuring the company and product brands reinforce each other in international markets.

The name change will be implemented this week and the company ASX ticker will change from EPT to PCK on 22nd January 2018.

“We thank our shareholders for supporting this strategic change which will hold us in good stead as we globalize the PainChek™ brand and business. We are updating our communications and collateral to align with the timing of the company name change. From now on it's the PainChek™ App from PainChek Ltd” commented Philip Daffas CEO and Managing Director of PainChek Ltd.


For further information contact:

Ian Hobson  
Company Secretary  
Tel: +61 8 9388 8290


Philip Daffas  
Managing Director  
Tel: +61 406-537-235

## The PainChek™ Technology:

PainChek™ uses cameras in smartphones and tablets to capture a brief video of the person, which is analysed in real time using facial recognition software to detect the presence of facial micro- expressions that are indicative of the presence of pain.



*PainChek™ artificial intelligence assesses facial micro-expressions that are indicative of the presence of pain*



*PainChek™ six domains of pain assessment that calculates pain severity score*

This data is then combined with other indicators of pain, such as vocalisations, behaviours and movements captured to calculate a pain severity score. Due to its speed, ease of use and it's reproducibility, PainChek™ will be able to be used to detect and measure a person's pain, and then further measurements can be used to monitor the effectiveness of pain management.

PainChek™ will be rolled out globally in two phases: first, PainChek™ which is designed for adults who are unable to effectively verbalise their pain such as people with dementia, and second, PainChek™ for Children who have not yet learnt to speak.